-
Innovation Ranking
NewInnovation Ranking – Ayala Corp
Ayala Corp (Ayala) is a business conglomerate with diversified business operations. It operates in real estate, financial services, water, telecommunications, automotive, power generation, transport infrastructure, electronics manufacturing services, business process outsourcing, education and healthcare industries. Ayala develops large-scale fully integrated residential and commercial communities; develops and sells residential, leisure and commercial lots. The company provides repairs and services for commercial vehicles and passenger cars; aviation including air-chartered services. The company also operates retail community clinics. Ayala’s manufacturing facilities are located...
-
Product Insights
NewNet Present Value Model: Ayala Pharmaceuticals, Incorporated’s AL-102
Empower your strategies with our Net Present Value Model: Ayala Pharmaceuticals, Incorporated's AL-102 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Ayala Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ayala Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of Ayala Land Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ayala Land Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Ayala Land/ Cathay Land – Southmont Mixed-Use Development – Calabarzon
Equip yourself with the essential tools needed to make informed and profitable decisions with our Ayala Land/ Cathay Land – Southmont Mixed-Use Development – Calabarzon report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MEM-288 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MEM-288 in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MEM-288 in Merkel Cell Carcinoma Drug Details: MEM-288 is under development...
-
Sector Analysis
NewPhilippines Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2028
Philippines Construction Market Overview The Philippines construction market size was $65.2 billion in 2023. The market will achieve an AAGR of more than 7% during 2025-2028. The government’s focus on infrastructure and energy development will support market expansion in real terms in 2024. Furthermore, the government’s focus on developing transport and energy infrastructure, along with investment to develop affordable housing and social infrastructure will drive the market growth during the forecast period. Philippines Construction Market Outlook, 2023-2028 ($ Billion) Buy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imvotamab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imvotamab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imvotamab in Diffuse Large B-Cell Lymphoma Drug Details: Imvotamab...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2023’, provides an overview of the Adenoid Cystic Carcinoma (ACC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...